Genmab Reports Significant Survival and Response Improvement in Interim Cancer Analysis

Genmab reported statistically significant, clinically meaningful improvement in overall survival and objective response with petosemtamab combination at the first interim analysis in first-line recurrent or metastatic PD-L1-positive head and neck cancer patients.